We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$214M
AUM Growth
+$9.71M
Cap. Flow
-$616K
Cap. Flow %
-0.29%
Top 10 Hldgs %
6.68%
Holding
490
New
42
Increased
186
Reduced
165
Closed
36

Top Buys

Rank Stock Value
1
OCCI
OFS Credit Co
OCCI
+$2.05M
2
HYG icon
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
+$1.92M
3
ECC
Eagle Point Credit Company
ECC
+$1.26M
4
APP icon
Applovin
APP
+$1.04M
5
CEG icon
Constellation Energy
CEG
+$1.01M

Top Sells

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$1.49M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.06M
3
GEN icon
Gen Digital
GEN
+$1.01M
4
ADBE icon
Adobe
ADBE
+$989K
5
STE icon
Steris
STE
+$907K

Sector Composition

Rank Sector Weight
1 Financials 28.16%
2 Healthcare 18.37%
3 Technology 14.33%
4 Industrials 8.16%
5 Consumer Discretionary 6.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
426
Nuvation Bio
NUVB
$2.27B
$70.6K 0.03%
30,821
+545
+2% +$1.66K
LQDA icon
427
Liquidia Corp
LQDA
$7.72B
$68.6K 0.03%
6,860
+119
+2% +$1.3K
NFE icon
428
New Fortress Energy
NFE
$95M
$68.6K 0.03%
7,543
+1,643
+28% +$25.3K
ARCT icon
429
Arcturus Therapeutics
ARCT
$161M
$67.8K 0.03%
2,919
+54
+2% +$1.16K
CVAC
430
DELISTED
CureVac
CVAC
$67.7K 0.03%
23,036
+405
+2% +$1.33K
ARWR icon
431
Arrowhead Research
ARWR
$12B
$67.4K 0.03%
3,478
+62
+2% +$1.51K
VIR icon
432
Vir Biotechnology
VIR
$1.46B
$66.6K 0.03%
8,894
+156
+2% +$1.35K
MGNX icon
433
MacroGenics
MGNX
$236M
$64.8K 0.03%
19,694
+351
+2% +$1.37K
STOK icon
434
Stoke Therapeutics
STOK
$1.81B
$64.6K 0.03%
5,256
+89
+2% +$1.26K
RXRX icon
435
Recursion Pharmaceuticals
RXRX
$1.6B
$64.3K 0.03%
9,763
+173
+2% +$1.24K
LRMR icon
436
Larimar Therapeutics
LRMR
$380M
$62.3K 0.03%
9,508
+166
+2% +$1.33K
ITOS
437
DELISTED
iTeos Therapeutics
ITOS
$57.7K 0.03%
5,655
+101
+2% +$1.54K
EDIT icon
438
Editas Medicine
EDIT
$394M
$57.3K 0.03%
16,790
+301
+2% +$1.31K
SANA icon
439
Sana Biotechnology
SANA
$857M
$53.6K 0.03%
12,890
+229
+2% +$1.2K
PGEN icon
440
Precigen
PGEN
$1.96B
$51.3K 0.02%
54,216
+966
+2% +$1.22K
LYEL icon
441
Lyell Immunopharma
LYEL
$321M
$49.1K 0.02%
1,779
+31
+2% +$911
PRME icon
442
Prime Medicine
PRME
$540M
$45.2K 0.02%
11,670
+211
+2% +$977
TSHA icon
443
Taysha Gene Therapies
TSHA
$1.59B
$44.4K 0.02%
22,103
+394
+2% +$864
FULC icon
444
Fulcrum Therapeutics
FULC
$246M
$42.2K 0.02%
11,813
+207
+2% +$1.54K
FDMT icon
445
4D Molecular Therapeutics
FDMT
$499M
$40.8K 0.02%
3,773
+64
+2% +$1.06K
ZNTL icon
446
Zentalis Pharmaceuticals
ZNTL
$330M
$35.6K 0.02%
9,683
+174
+2% +$632
CABA icon
447
Cabaletta Bio
CABA
$432M
$34.6K 0.02%
7,338
+131
+2% +$758
AGEN
448
Agenus
AGEN
$280M
$31.6K 0.01%
5,759
+101
+2% +$756
KYTX icon
449
Kyverna Therapeutics
KYTX
$430M
$31.2K 0.01%
6,381
+112
+2% +$863
ALXO icon
450
ALX Oncology
ALXO
$261M
$19.9K 0.01%
10,920
+194
+2% +$721
16 17
18
19 20

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q3 2024 Portfolio in Review

As of Q3 2024, Virtus ETF Advisers held 490 positions worth $214M, up 4.8% from $204M the previous quarter. Its ten largest holdings account for 6.7% of the portfolio.

Virtus ETF Advisers's Q3 2024 filing shows 42 new, 186 increased, 165 reduced and 36 closed positions. Its largest new stake was OFS Credit Co: 278,579 shares worth $2.06M. The largest sale was Oxford Lane Capital, an estimated $1.49M.

By sector, the portfolio is most concentrated in Financials at 28% of assets, up from 27% a quarter earlier, followed by Healthcare and Technology.

  • Virtus ETF Advisers's largest Q3 2024 buy was OFS Credit Co: 278,579 shares worth $2.06M.
  • Virtus ETF Advisers added most to Public Storage in Q3 2024, an estimated $927K increase.
  • Virtus ETF Advisers's biggest Q3 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.06M.
  • Virtus ETF Advisers fully exited Oxford Lane Capital in Q3 2024, selling an estimated $1.49M.
  • Virtus ETF Advisers's ten largest holdings make up 6.7% of its $214M portfolio in Q3 2024.
  • Virtus ETF Advisers opened 42 new positions and closed 36 in Q3 2024.
  • Virtus ETF Advisers's portfolio value rose 4.8% quarter-over-quarter to $214M.

Based on Virtus ETF Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.